Ariel B. Bourla

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 396 citations · Full text

Medicine, Oncology, Pharmacology +17

Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set

Sandra D. Griffith, Rebecca A. Miksad, Geoff Calkins et al. · JCO Clinical Cancer Informatics · 2019 · 107 citations · Full text

Medicine, Biomedical Informatics, Health Informatics +16

Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer

Cynthia Huang Bartlett, Jack Mardekian, Matthew J. Cotter et al. · PLoS ONE · 2020 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC

Xinran Ma, Lawrence Bellomo, Kelly Magee et al. · Advances in Therapy · 2021 · 48 citations · Full text

Medicine, Oncology, Electronic Health Records +16

Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types

Aracelis Z. Torres, Nathan C. Nussbaum, Christina M. Parrinello et al. · Advances in Therapy · 2022 · 26 citations · Full text

Computing, Health Informatics, Oncology +17